Cantor Fitzgerald Investment Advisors L.P. grew its holdings in shares of CVS Health Corporation (NYSE:CVS – Free Report) by 2.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 260,592 shares of the pharmacy operator’s stock after purchasing an additional 6,402 shares during the period. CVS Health makes up approximately 1.2% of Cantor Fitzgerald Investment Advisors L.P.’s holdings, making the stock its 17th largest position. Cantor Fitzgerald Investment Advisors L.P.’s holdings in CVS Health were worth $22,330,000 as of its most recent SEC filing.
A number of other institutional investors have also recently modified their holdings of the stock. Granite Islands Private Wealth LLC lifted its holdings in shares of CVS Health by 185.0% during the 3rd quarter. Granite Islands Private Wealth LLC now owns 11,769 shares of the pharmacy operator’s stock valued at $1,008,000 after buying an additional 7,639 shares during the period. Ellsworth Advisors LLC boosted its stake in shares of CVS Health by 5.3% during the 3rd quarter. Ellsworth Advisors LLC now owns 38,943 shares of the pharmacy operator’s stock worth $3,337,000 after acquiring an additional 1,975 shares during the last quarter. Neumann Capital Management LLC lifted its holdings in CVS Health by 2.9% during the third quarter. Neumann Capital Management LLC now owns 38,751 shares of the pharmacy operator’s stock valued at $3,321,000 after purchasing an additional 1,100 shares in the last quarter. NFSG Corp raised its holdings in CVS Health by 954.0% during the third quarter. NFSG Corp now owns 527 shares of the pharmacy operator’s stock valued at $45,000 after acquiring an additional 477 shares during the period. Finally, V Square Quantitative Management LLC grew its stake in CVS Health by 22.6% during the third quarter. V Square Quantitative Management LLC now owns 7,491 shares of the pharmacy operator’s stock valued at $642,000 after acquiring an additional 1,381 shares in the last quarter. 80.66% of the stock is owned by hedge funds and other institutional investors.
CVS Health Stock Performance
NYSE CVS opened at $92.45 on Friday. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.74. The stock has a market capitalization of $118.25 billion, a price-to-earnings ratio of 24.46, a PEG ratio of 0.84 and a beta of 0.60. The stock has a 50-day moving average of $91.80 and a 200 day moving average of $93.03. CVS Health Corporation has a twelve month low of $69.51 and a twelve month high of $110.68.
CVS Health (NYSE:CVS – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.87 by $0.71. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The company had revenue of $106.10 billion during the quarter, compared to analysts’ expectations of $100.03 billion. During the same quarter in the prior year, the company earned $1.81 EPS. CVS Health’s revenue was up 7.3% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Sell-side analysts anticipate that CVS Health Corporation will post 8.02 EPS for the current fiscal year.
CVS Health Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Thursday, October 22nd will be given a dividend of $0.6650 per share. This represents a $2.66 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend is Thursday, October 22nd. CVS Health’s dividend payout ratio (DPR) is 70.37%.
Key Headlines Impacting CVS Health
Here are the key news stories impacting CVS Health this week:
- Positive Sentiment: Improving fundamentals and valuation support the stock. CVS has recently exceeded earnings and revenue expectations, while analysts cited stronger returns, rising earnings estimates and a lower valuation than Alignment Healthcare. Its Aetna turnaround is also viewed as a potential catalyst. CVS vs. ALHC: Which Medicare Advantage Stock Is the Better Pick Now?
- Positive Sentiment: Expanded care access and quality credentials reinforce CVS’s healthcare-services strategy. CVS opened its first pharmacy-focused location in the Boston area to improve access to medications, immunizations and other services. Separately, MinuteClinic received its seventh consecutive Joint Commission accreditation, with primary care available at more than 65% of its locations. CVS Pharmacy Celebrates Opening of First Pharmacy-Focused Location in Boston Area
- Neutral Sentiment: New women’s-health collaboration could support longer-term engagement. CVS is partnering with The Midlife Collective on a research study and documentary focused on women’s midlife health. The initiative may strengthen brand awareness and consumer relationships, but it is unlikely to have a near-term financial impact. CVS Health Collaborates With The Midlife Collective
- Positive Sentiment: Home-based heart monitoring expands value-added services. Signify Health, part of CVS, offers continuous heart-rhythm monitoring for eligible health-plan members, potentially enabling earlier detection of serious conditions and supporting preventive-care economics. CVS Health: Early Detection Matters
- Negative Sentiment: $315 million opioid settlement creates legal, financial and reputational pressure. CVS agreed to settle Justice Department allegations involving unlawful opioid dispensing and false claims. The company admitted no wrongdoing but will implement tighter controlled-substance oversight, adding costs and highlighting compliance risks. CVS Agrees to Pay $315M
Analyst Upgrades and Downgrades
Several equities research analysts have recently issued reports on CVS shares. Robert W. Baird set a $107.00 price objective on CVS Health in a research note on Thursday, August 6th. Bank of America upped their price target on shares of CVS Health from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Monday, June 22nd. Royal Bank Of Canada increased their price objective on CVS Health from $107.00 to $113.00 and gave the stock an “outperform” rating in a research note on Thursday, July 9th. BMO Capital Markets set a $112.00 price target on CVS Health in a research note on Wednesday, September 9th. Finally, Wall Street Zen raised shares of CVS Health from a “buy” rating to a “strong-buy” rating in a research note on Sunday, October 11th. Twenty analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, CVS Health currently has an average rating of “Moderate Buy” and a consensus target price of $107.80.
Check Out Our Latest Analysis on CVS Health
CVS Health Profile
CVS Health Corp. is an integrated health care company that provides pharmacy, insurance and health services primarily in the United States. Its operations are designed to connect consumers, health plans, health care providers and pharmacy services across multiple points of care.
The company’s major businesses include CVS Pharmacy retail locations, prescription fulfillment and consumer health products; CVS Caremark, a pharmacy benefit management business; and Aetna, which offers health insurance products and related services for employers, individuals, government programs and other organizations.
Featured Stories
- Five stocks we like better than CVS Health
- ASML Can’t Keep Up With AI Demand—Why That’s a Good Thing
- Enovix’s 100,000-Battery Drone Order Sets Up a Test of Its Production Plans
- AMD’s Support Could Help Fermi Stock Overcome Its Biggest Hurdle
- Beyond the GPU: Credo Paves the Next AI Data Superhighway
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS – Free Report).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.
